BCL2 and hepatocellular carcinoma: We first knocked down PDCD2L in two p53-mutant hepatocellular carcinoma cells (MHCC97H and Huh7) and found that the expression of p53, p21, and bax was increased, and the expression of bcl2 was decreased, while the overexpression of PDCD2L was vice versa.